Dasatinib
- Generic Name
- Dasatinib
- Brand Names
- Sprycel
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26ClN7O2S
- CAS Number
- 302962-49-8
- Unique Ingredient Identifier
- X78UG0A0RN
- Background
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...
- Indication
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)
- Conditions
- Interventions
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3
- Registration Number
- NCT00500006
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
- Conditions
- Interventions
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 204
- Registration Number
- NCT00495872
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2010-12-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 23
- Registration Number
- NCT00482703
- Locations
- 🇯🇵
Local Institution, Kyoto, Japan
A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 547
- Registration Number
- NCT00481247
- Locations
- 🇺🇸
Molecular Md, Portland, Oregon, United States
🇹🇷Local Institution, Kayseri, Turkey
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT00474812
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00470054
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Trial of Dasatinib in Advanced Sarcomas
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2018-11-23
- Target Recruit Count
- 366
- Registration Number
- NCT00464620
- Locations
- 🇺🇸
Washington Cancer Institute, Washington, District of Columbia, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Kootenai Cancer Center, Coeur d'Alene, Idaho, United States
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00459108
- Locations
- 🇺🇸
University of Southern California, Norris, Los Angeles, California, United States
Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00459342
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Expanded Access for Dasatinib
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00454753
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.